PMEL and melanoma: The list of ongoing clinical trials using TCR-engineered T cells is progressively expanding, with most of them directed against well characterized tumor-expressed antigens such as gp100 and tyrosinase for melanoma, WT1 for AML and NSCLC, HPV-6 for HPV-associated cancers and others [235,236].